PMID- 30496023
OWN - NLM
STAT- MEDLINE
DCOM- 20190822
LR  - 20190822
IS  - 1362-3095 (Electronic)
IS  - 0955-3002 (Linking)
VI  - 95
IP  - 3
DP  - 2019 Mar
TI  - Assessment of the dicentric chromosome assay as a biodosimetry tool for more 
      personalized medicine in a case of a high risk neuroblastoma (131)I-mIBG 
      treatment.
PG  - 314-320
LID - 10.1080/09553002.2019.1549755 [doi]
AB  - PURPOSE: The aims of this study were to estimate the whole - body absorbed - dose 
      with the Dicentric Chromosome Assay (DCA) (biodosimetry) for (131)I - 
      metaiodobenzylguanidine ((131)I - mIBG) therapy for high - risk neuroblastoma, 
      and to obtain an initial correlation with the physical dosimetry calculated as 
      described by the Medical Internal Radiation Dosimetry formalism (MIRD). Together 
      both objectives will aid the optimization of personalized targeted radionuclide 
      therapies. MATERIAL AND METHODS: A 12 year-old child with relapsed high-risk 
      neuroblastoma was treated with (131)I-mIBG: a first administration with activity 
      <444 MBq/kg was used as a tracer in order to calculate the activity needed in a 
      second administration to achieve a whole body prescribed dose of  approximately 4 Gy. Blood 
      samples were obtained before and seven days after each administration to analyze 
      the frequency of dicentrics. Moreover, consequent estimations of retained 
      activity were done every few hours from equivalent dose rate measurements at a 
      fixed position, two meters away from the patient, in order to apply the MIRD 
      procedure. Blood samples were also drawn every 2- to -3 days to assess bone 
      marrow toxicity. RESULTS: For a total activity of 22,867 MBq administered over 
      two phases, both biological and physical dosimetries were performed. The former 
      estimated a whole-body cumulated dose of 3.53 (2.58-4.41) Gy and the latter a 
      total whole-body absorbed dose of 2.32 +/- 0.48 Gy. The patient developed 
      thrombocytopenia grade 3 after both infusions and neutropenia grade 3 and grade 4 
      (based on CTCAE 4.0) during respective phases. CONCLUSION: The results indicate a 
      possible correlation between biodosimetry and standard physical dosimetry in 
      (131)I-mIBG treatment for high-risk neuroblastoma. A larger cohort and refinement 
      of the DCA for internal irradiation are needed to define the role of biodosimetry 
      in clinical situations.
FAU - Chimeno, Jose Maria
AU  - Chimeno JM
AD  - a Radiation Protection Service , Hospital Universitario y Politecnico La Fe , 
      Valencia , Spain.
FAU - Sebastia, Natividad
AU  - Sebastia N
AD  - a Radiation Protection Service , Hospital Universitario y Politecnico La Fe , 
      Valencia , Spain.
AD  - b Mixed Unity of Nanomedicine and Sensors , Instituto de Investigacion Sanitaria 
      La Fe Valencia , Spain.
FAU - Torres-Espallardo, Irene
AU  - Torres-Espallardo I
AD  - c Department of Nuclear Medicine , Hospital Universitario y Politecnico La Fe , 
      Valencia , Spain.
FAU - Balaguer, Julia
AU  - Balaguer J
AD  - d Department of Pediatric Oncology , Hospital Universitario y Politecnico La Fe , 
      Valencia , Spain.
FAU - Candela-Juan, Cristian
AU  - Candela-Juan C
AD  - e Centro Nacional de Dosimetria (CND) , Instituto Nacional de Gestion Sanitaria , 
      Valencia , Spain.
FAU - Loaiza, Jose Luis
AU  - Loaiza JL
AD  - c Department of Nuclear Medicine , Hospital Universitario y Politecnico La Fe , 
      Valencia , Spain.
FAU - Adria, Mar
AU  - Adria M
AD  - c Department of Nuclear Medicine , Hospital Universitario y Politecnico La Fe , 
      Valencia , Spain.
FAU - Ibanez-Rosello, Blanca
AU  - Ibanez-Rosello B
AD  - c Department of Nuclear Medicine , Hospital Universitario y Politecnico La Fe , 
      Valencia , Spain.
FAU - Canete, Adela
AU  - Canete A
AD  - d Department of Pediatric Oncology , Hospital Universitario y Politecnico La Fe , 
      Valencia , Spain.
FAU - Marti-Bonmati, Luis
AU  - Marti-Bonmati L
AD  - f Department of Radiology , Hospital Universitario y Politecnico La Fe and 
      Instituto de Investigacion Sanitaria la Fe , Valencia , Spain.
AD  - g Biomedical Imaging Research Group GIBI230 , Instituto de Investigacion 
      Sanitaria la Fe , Spain.
FAU - Montoro, Alegria
AU  - Montoro A
AD  - a Radiation Protection Service , Hospital Universitario y Politecnico La Fe , 
      Valencia , Spain.
AD  - g Biomedical Imaging Research Group GIBI230 , Instituto de Investigacion 
      Sanitaria la Fe , Spain.
LA  - eng
PT  - Journal Article
DEP - 20190111
PL  - England
TA  - Int J Radiat Biol
JT  - International journal of radiation biology
JID - 8809243
RN  - 35MRW7B4AD (3-Iodobenzylguanidine)
MH  - 3-Iodobenzylguanidine/*therapeutic use
MH  - Adult
MH  - Child
MH  - Chromosome Aberrations/*radiation effects
MH  - Humans
MH  - Neuroblastoma/*radiotherapy
MH  - *Precision Medicine
MH  - Radiometry/*methods
MH  - Risk
OTO - NOTNLM
OT  - Biodosimetry
OT  - mIBG therapy
OT  - neuroblastoma
EDAT- 2018/11/30 06:00
MHDA- 2019/08/23 06:00
CRDT- 2018/11/30 06:00
PHST- 2018/11/30 06:00 [pubmed]
PHST- 2019/08/23 06:00 [medline]
PHST- 2018/11/30 06:00 [entrez]
AID - 10.1080/09553002.2019.1549755 [doi]
PST - ppublish
SO  - Int J Radiat Biol. 2019 Mar;95(3):314-320. doi: 10.1080/09553002.2019.1549755. 
      Epub 2019 Jan 11.